Earnings Analysis October 30, 2026

OmniAb ($OABI) Q3 2026 Earnings Analysis: Revenue Beats Estimates · Guidance Raised, Stock Falls 12.72%

Earnings Report

Revenue: $4 million (up 78.4% YoY, vs. $3.49 million expected) ✅ Beat

EPS (Earnings Per Share): -$0.12 (GAAP, vs. -$0.13 expected) ✅ Beat

Guidance: Raised, annual revenue $35 million–$39 million (previously $32 million–$36 million)

Stock Reaction: -12.72% in regular trading ($4.565, as of 10-30 23:15 KST)

Highlights

78% Revenue Increase: Q3 revenue reached $4 million, up 78.4% from $2.24 million in the same period last year.

Raised Guidance: The annual revenue outlook was raised to $35 million–$39 million.

New Contract with Lilly: Ion channel program agreement with Eli Lilly, with milestones up to $370 million.

Cash and cash equivalents were maintained at $64.2 million, and R&D expenses decreased to $9.55 million from $10.38 million in the same period last year. Cash expenses and operating expenses also remained largely consistent with previous year levels at $13.7 million.

Lowlights

Sharp Drop in Licensing Revenue: Q3 licensing and milestone revenue was $100,000, compared to $616,000 in the same period last year.

Continued Deficit: Q3 net loss was $15.73 million, or -$0.12 per share.

Increase in G&A Expenses: Increased to $7.24 million from $6.78 million in the same period last year.

However, the net loss narrowed from $16.53 million in the same period last year to $15.73 million. The 78% increase in revenue offset the rise in expenses.

What the Company Said

CEO Matt Foehr explained that Q3 performance stemmed from the execution of licensing agreements and an efficient cost structure. The company raised both its annual revenue and cash outlook once again.

Market Reaction and Key Points to Watch

While total revenue exceeded expectations, the weight of Q3 revenue was centered on services and equipment sales. Licensing and milestone revenue fell to $100,000 from $616,000 in the same period last year, and the $21.54 million in milestones recognized in the first half of the year was absent in Q3.

A key point to monitor is whether remaining milestones in Q4 and new licensing agreements will meet the annual revenue outlook of $35 million–$39 million.

It is necessary to watch whether exploration revenue reaches the $2 million–$3 million forecast for 2026 and if the first signs of twofold growth in 2027 emerge.

The scale of the upfront payment from the Lilly contract and the trend of Q4 R&D expenses will determine the cash burn rate.

Earnings Call Summary

Once the earnings call concludes and the company script is released, the key takeaways from the call will be added here. We will select and summarize only the most important points, such as how management explained performance and outlook, and what questions analysts asked.